| Dr Daniel D Varnell Ii, MD | |
|
1012 South Third Street, Dayton, WA 99328 | |
| (509) 382-3200 | |
| (509) 382-2748 |
| Full Name | Dr Daniel D Varnell Ii |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 1012 South Third Street, Dayton, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649240532 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | MD00046806 (Washington) | Primary |
| Entity Name | Multicare Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1497766638 PECOS PAC ID: 7719899897 Enrollment ID: O20031105000760 |
News Archive
HealthCare Royalty Partners ("HC Royalty"), a global healthcare investment firm, today announced the closing on $1.5 billion for HealthCare Royalty Partners III, L.P. ("Fund III") and affiliated entities.
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc., today announced that it has received clearance from the Therapeutic Goods Administration (TGA) for its illumigene Group B Streptococcus (GBS) test, the newest molecular product on the illumigene platform.
UCLA AIDS Institute researchers successfully removed CCR5 - a cell receptor to which HIV-1 binds for infection but which the human body does not need - from human cells. Individuals who naturally lack the CCR5 receptor have been found to be essentially resistant to HIV.
Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.
› Verified 3 days ago
| Entity Name | Navos |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194728105 PECOS PAC ID: 4385545474 Enrollment ID: O20040120001086 |
News Archive
HealthCare Royalty Partners ("HC Royalty"), a global healthcare investment firm, today announced the closing on $1.5 billion for HealthCare Royalty Partners III, L.P. ("Fund III") and affiliated entities.
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc., today announced that it has received clearance from the Therapeutic Goods Administration (TGA) for its illumigene Group B Streptococcus (GBS) test, the newest molecular product on the illumigene platform.
UCLA AIDS Institute researchers successfully removed CCR5 - a cell receptor to which HIV-1 binds for infection but which the human body does not need - from human cells. Individuals who naturally lack the CCR5 receptor have been found to be essentially resistant to HIV.
Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.
› Verified 3 days ago
| Entity Name | Reliance Medical Clinics, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982734273 PECOS PAC ID: 3375635121 Enrollment ID: O20070823000886 |
News Archive
HealthCare Royalty Partners ("HC Royalty"), a global healthcare investment firm, today announced the closing on $1.5 billion for HealthCare Royalty Partners III, L.P. ("Fund III") and affiliated entities.
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc., today announced that it has received clearance from the Therapeutic Goods Administration (TGA) for its illumigene Group B Streptococcus (GBS) test, the newest molecular product on the illumigene platform.
UCLA AIDS Institute researchers successfully removed CCR5 - a cell receptor to which HIV-1 binds for infection but which the human body does not need - from human cells. Individuals who naturally lack the CCR5 receptor have been found to be essentially resistant to HIV.
Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Daniel D Varnell Ii, MD 1012 South Third Street, Dayton, WA 99328 Ph: (509) 382-3200 | Dr Daniel D Varnell Ii, MD 1012 South Third Street, Dayton, WA 99328 Ph: (509) 382-3200 |
News Archive
HealthCare Royalty Partners ("HC Royalty"), a global healthcare investment firm, today announced the closing on $1.5 billion for HealthCare Royalty Partners III, L.P. ("Fund III") and affiliated entities.
Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc., today announced that it has received clearance from the Therapeutic Goods Administration (TGA) for its illumigene Group B Streptococcus (GBS) test, the newest molecular product on the illumigene platform.
UCLA AIDS Institute researchers successfully removed CCR5 - a cell receptor to which HIV-1 binds for infection but which the human body does not need - from human cells. Individuals who naturally lack the CCR5 receptor have been found to be essentially resistant to HIV.
Acetylon Pharmaceuticals Inc., a leader in targeted epigenetic drug discovery and development for enhanced therapeutic outcomes, today announced results from a preclinical study of a selective histone deacetylase (HDAC) 1/2 inhibitor for the treatment of sickle cell disease (SCD) and beta-thalassemia (bT) at the 54th Annual Meeting of the American Society of Hematology (ASH), taking place in Atlanta, Georgia.
› Verified 3 days ago